<DOC>
	<DOC>NCT02599792</DOC>
	<brief_summary>Two-part study to assess CTP-656 dosed as a solid oral dosage form versus Kalydeco and multiple-ascending doses of CTP-656 dosed for 7 days.</brief_summary>
	<brief_title>Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656</brief_title>
	<detailed_description>This two-part study will assess in healthy male and female subjects a solid oral dose formulation of CTP-656 vs. Kalydeco® and the safety, tolerability and pharmacokinetic profiles of escalating CTP-656 solid oral doses following 7 days of dosing. In Part B, three doses of CTP-656 ranging from 75 mg up to 300 mg per day will be studied.</detailed_description>
	<criteria>Healthy adults between 18 and 50 years of age, inclusive Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at screening History of clinically significant central nervous system (eg, seizures), cardiac, pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of Gilbert's syndrome or gastrointestinal (GI) conditions PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcF interval &gt; 450 msec obtained at screening visit or prior to the first dose of study drug Liver function tests greater than the upper limit of normal. Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening Urinalysis positive for greater than trace blood, protein or glucose A positive screen for alcohol, drugs of abuse, or tobacco use. Inability to comply with food and beverage restrictions during study participation. Donation or blood collection or acute loss of blood prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Safety and Pharmacokinetics</keyword>
</DOC>